Anti-Aging Stack

The Anti-Aging Stack combines three compounds that research suggests operate on fundamentally different biological clocks. Epithalon is a synthetic tetrapeptide studied for its ability to reactivate telomerase — the enzyme that maintains chromosome ends — in somatic cells that have normally silenced it [PMID: 12398480]. GHK-Cu is a naturally occurring copper-binding tripeptide that circulates in human plasma at concentrations that decline dramatically with age, studied for its role in collagen synthesis and antioxidant gene regulation [PMID: 22512572]. NAD+ is an essential coenzyme whose tissue levels drop significantly over the lifespan, serving as substrate for sirtuins, PARP enzymes, and mitochondrial electron transport [PMID: 24786309].

What distinguishes this combination from single-compound approaches is the apparent absence of mechanistic redundancy. Epithalon research focuses on the telomere-telomerase axis — the chromosomal erosion that limits cell division capacity. GHK-Cu studies examine the extracellular matrix and tissue remodeling — the structural degradation of skin, connective tissue, and vasculature. NAD+ research targets cellular bioenergetics and genomic maintenance — the metabolic decline and DNA damage accumulation that characterize aging at the molecular level. These three domains represent distinct hallmarks of biological aging as defined in the geroscience literature.

All three compounds are classified as research substances with evidence drawn primarily from preclinical models and, in the case of NAD+ precursors, early-stage human clinical trials. No regulatory agency has approved this combination for human therapeutic use. The information on this page reflects published scientific literature as a resource for researchers.

The research rationale for combining Epithalon, GHK-Cu, and NAD+ rests on their targeting of non-overlapping hallmarks of biological aging.

Epithalon addresses telomere attrition — the progressive shortening of chromosome ends that occurs with each cell division. Research suggests this tetrapeptide may reactivate telomerase reverse transcriptase (hTERT) in somatic cells, potentially extending replicative lifespan [PMID: 12398480]. Studies in animal models have reported mean lifespan extension associated with chronic epitalon administration [PMID: 15865243]. Additionally, research indicates epitalon may restore age-declined nocturnal melatonin secretion through pinealocyte resensitization, addressing the circadian disruption common in aging populations [PMID: 10709557].

GHK-Cu operates at the tissue architecture level. Endogenous GHK-Cu plasma concentrations decline from approximately 200 ng/mL in young adults to near-undetectable levels in older individuals [PMID: 25007386]. Studies suggest the peptide stimulates fibroblast production of collagen and elastin — the structural proteins that maintain skin firmness and connective tissue integrity [PMID: 22512572]. Research also indicates GHK-Cu may upregulate antioxidant defense genes including superoxide dismutase, representing a gene-regulatory approach to oxidative stress rather than passive radical scavenging [PMID: 22512572]. Its role in angiogenesis promotion adds a vascular dimension relevant to tissue repair and nutrient delivery [PMID: 25007386].

NAD+ functions as a critical metabolic and genomic maintenance coenzyme. It serves as substrate for sirtuin family deacetylases (SIRT1–7), which regulate mitochondrial function, metabolic homeostasis, and stress response pathways [PMID: 24786309]. NAD+ is also consumed by PARP-1 and PARP-2 enzymes during DNA single-strand break repair — a process that becomes increasingly demanding as genomic damage accumulates with age [PMID: 31065944]. Research has identified CD38 glycohydrolase as a key driver of age-related NAD+ decline, with CD38 expression increasing in aging tissues and depleting cellular NAD+ pools [PMID: 26785480].

The mechanistic logic is that these three compounds address different layers of the aging process simultaneously: chromosomal maintenance (Epithalon), structural tissue integrity (GHK-Cu), and cellular energy/DNA repair capacity (NAD+). No direct study has tested this specific three-compound combination, and the synergy rationale is extrapolated from independent preclinical research on each compound.

The three compounds in this stack differ substantially in their studied administration routes and dosing patterns, which introduces complexity into combined protocol design.

Epithalon has been studied primarily via subcutaneous injection at 5–10 mg per day in short courses of approximately 10 days, with periodic repetition every few months [PMID: 15865243]. This pulsatile approach reflects the hypothesis that brief telomerase activation triggers sustained transcriptional changes without requiring continuous exposure. The peptide's extremely short plasma half-life (minutes) belies these longer-term biological effects. Intranasal delivery has been explored in some research contexts but lacks standardized dosing protocols.

GHK-Cu research has employed both topical (0.1–1% concentration in dermatological formulations) and subcutaneous routes [PMID: 22512572]. The peptide's short plasma half-life (minutes to hours) necessitates repeated administration for sustained tissue exposure. Topical application targets skin-specific endpoints (collagen synthesis, wound healing), while subcutaneous delivery aims for systemic tissue remodeling effects. The copper-binding nature of GHK-Cu means that formulation chemistry — pH, solvent, penetration enhancers — significantly affects bioavailability.

NAD+ is most commonly studied through oral precursor supplementation rather than direct NAD+ administration. Clinical trials have explored nicotinamide riboside (NR) at 100–2000 mg/day and nicotinamide mononucleotide (NMN) at 250–900 mg/day, both showing dose-dependent elevation of blood NAD+ levels [PMID: 29184669, 32320006, 36482258]. Intravenous and subcutaneous NAD+ administration have also been reported in research settings but lack the clinical trial infrastructure of oral precursors.

Combining these three compounds requires reconciling different delivery schedules: pulsatile subcutaneous Epithalon courses, regular GHK-Cu administration (topical or injectable), and daily oral NAD+ precursor supplementation. No consensus combined protocol exists in the literature. All dosing information derives from independent studies on individual compounds and should be treated as preliminary research-context reference points.